CClinicalTrials.gg
CompletedNCT01332864OMTHAUpdated Feb 13, 2013

Effect of Osteopathic Manipulative Treatment for Patients With Chronic Headache

A Phase 4 interventional study of Osteopathic Manipulative Treatment (OMT) and Light touch in Headache, Cephalgia and Migraine, sponsored by Western University of Health Sciences. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2013-02-13.

Sponsored by Western University of Health Sciences · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Study summary

Participants with chronic or recurrent headache, unrelated to any known pathology or disease, will be randomly assigned to one of four interventions: Osteopathic manipulation of the body other than the head, osteopathic manipulation of the head, osteopathic manipulation of the head and rest of the body, or light touch on the head only but no manipulation. Measurements of heart rate and blood pressure variability, peripheral blood flow, and behavioral changes, such as mood, pain duration, intensity and frequency will be assessed.

Read the detailed description

Sixty subjects will be recruited to participate in the study via word of mouth and mass email notification of employees and students at Western University of Health Sciences in Pomona, CA.

Patients will be randomly assigned to 1 of 4 groups for a specific Osteopathic Manipulative Treatment (OMT): Compression of Fourth Ventricle (CV4) only, CV4 and subject appropriate OMT, subject appropriate OMT only (no CV4), and sham (touch only). There will be 8 subjects per OMT group, making it 24 subjects altogether assigned to one of the three OMT groups, and 24 sham subjects.

Power analysis for determination of sample sizes: The investigators have no data on preliminary studies of the effect of OMT on chronic headaches, and there is only one study of the immediate effect on tension type headache patients after CV4, so power analysis is a rough estimate at this point for the one week headache symptom evaluation post OMT. From preliminary studies in this lab, the investigators can expect for 'CV4 only' 80% of participants to have significant still point objective response vs sham treatment which the investigators expect will significantly effect about 10% of the participants. There needs to be at least 16 subjects in each of two groups assessing this outcome measure, so 16 receiving CV4 and 16 sham to detect the 70% difference in still point measure. To detect differences between any OMT and sham, since there are three groups receiving OMT of some type, when the investigators consider how many in each of these three groups vs the sham group, the investigators figured 8 per each OMT group, of which 2 are CV4 (thus 16 get CV4), making it 24 subjects in the combined OMT groups. Therefore, the investigators need 24 sham subjects to make it equal numbers for balanced analysis (OMT vs sham), and to detect differences in the OMT interventions and sham interventions. Considering a possibility of 25%, or 12 subjects, not responding to the follow up survey at one week, the investigators figured recruitment of 60 subjects would ensure the investigators would have enough to make our calculations and be able to determine if there are significant differences between groups.

The investigators have no preliminary studies on the effect of OMT or sham on mood in patient with headaches, so this part of the study is an exploratory assessment and sample size calculations will be able to be performed with the data gathered from this study for subsequent studies.

02

Conditions studied

  • Headache
  • Cephalgia
  • Migraine

Keywords

  • headache
  • migraine
  • cephalgia
  • osteopathic manipulative treatment
03

In context

Headache Disorders

162 studies on the registry are indexed under Headache Disorders; 40 are open to participants now.

This study's enrollment of 60 is close to the median of 60 across 103 interventional studies indexed under Headache Disorders.

Browse Headache Disorders studies →

Lead sponsor

Western University of Health Sciences is the lead sponsor of 21 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • chronic or recurrent headaches at least as often as one time per week

Exclusion criteria

Exclusion Criteria:

  • recent head trauma
  • brain disease or pathology
  • seizure disorder
  • using beta or alpha blocker medications
  • allergy to sticky tape used to affix leads to skin
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    OMT to the head and rest of body

    OMT is the intervention that will be applied to areas of somatic dysfunction as well as to the head using a compression of the fourth ventricle (CV4) technique.

    Procedure: Osteopathic Manipulative Treatment (OMT)

  • Placebo comparator
    Light touch

    Light touch will be applied to the head region for 10 minutes with the patient at rest in the supine position.

    Procedure: Light touch

  • Experimental
    OMT with CV4 to head

    OMT is the intervention using the CV4 technique to the head region for 10 minutes with patient at rest.

    Procedure: Osteopathic Manipulative Treatment (OMT)

  • Active comparator
    OMT to the body except the head region

    OMT is the intervention that will be applied to areas of somatic dysfunction in any region except the head.

    Procedure: Osteopathic Manipulative Treatment (OMT)

Interventions

  • ProcedureOsteopathic Manipulative Treatment (OMT)

    O OMT applied to areas of somatic dysfunction other than the head region.

    Also known as: headache; OMT; somatic dysfunction ICD-9 code 739.0

  • ProcedureLight touch

    Light touch applied to head region for 10 minutes with patient supine at rest.

    Also known as: placebo; sham

06

What researchers measure

Primary outcomes

  1. Head pain frequency

    seven days after the intervention participants will be called by telephone and asked whether they had their usual headache in the week following the intervention.

    Time frame: one week after intervention

Secondary outcomes

  1. Head pain intensity

    one week after intervention participants will be contacted and asked to rate the intensity of their headaches after the intervention.

    Time frame: one week

  2. Head pain duration

    one week after the intervention participants will be contacted and asked the duration of the headaches.

    Time frame: one week

07

Study locations

1 site
  • Western University of Health Sciences
    Pomona, California 91766, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01332864
Lead sponsor
Western University of Health Sciences
Responsible party
Michael Seffinger (Principal Investigator, Associate Professor and Chair of Dept. of NMM/OMM, Western University of Health Sciences) — Principal investigator
First posted
Apr 11, 2011
Start date
Mar 2011
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Feb 13, 2013

Study contacts

Michael A. Seffinger, D.O.
principal investigator · Western University of Health Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion